Peter Clausen - 01 Jan 2022 Form 3/A - Amendment Insider Report for Nuo Therapeutics, Inc. (AURX)

Role: CSO/COO
Signature: /s/ David E. Jorden, attorney-in-fact
Issuer symbol: AURX
Transactions as of: 01 Jan 2022
Net transactions value: $0
Form type: 3/A - Amendment
Filing time: 18 Oct 2022, 13:20:46 UTC
Date Of Original Report: 26 Apr 2022
Next filing: 26 Apr 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	AURX	Common Stock						501,201	01 Jan 2022	Direct
holding	AURX	Common Stock						3,474	01 Jan 2022	By spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	AURX	Option to Purchase Common Stock							01 Jan 2022	Common Stock	183,853	$0.4000	Direct
holding	AURX	Option to Purchase Common Stock							01 Jan 2022	Common Stock	81,250	$0.4000	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Remarks:

(1) Dr. Clausen served as our Chief Scientific Officer until December 31, 2019 and was reappointed as our Chief Scientific Officer as well as our Chief Operating Officer effective January 1, 2022 (2) This amendment corrects an inadvertent error in the amount of indirect shares owned in Table 1. This amendment also adds Table II securities that were inadvertently omitted from the Form 3 as originally filed.